GILD
HealthcareGilead Sciences, Inc.
$118.30
$-3.30 (-2.71%)
Jan 5, 2026
Price History (1Y)
Analysis
Gilead Sciences, Inc. is a healthcare company operating in the drug manufacturers - general industry, with a significant scale of operations. The company has a market capitalization of $146.79 billion and generates revenue of approximately $29.09 billion on a trailing 12-month basis, employing around 17,600 individuals. The financial health of Gilead Sciences, Inc. is characterized by substantial profitability. The company boasts gross margin, operating margin, and profit margin rates of 78.7%, 45.2%, and 27.9%, respectively. In terms of returns, the return on equity (ROE) stands at 40.7% and return on assets (ROA) is 12.6%. The balance sheet shows a significant amount of debt ($24.94 billion), but also substantial cash reserves ($8.49 billion). Gilead Sciences, Inc.'s valuation context features an earnings per share (EPS) ratio of 18.84 and forward P/E of 13.53. The company's revenue growth rate is relatively stable at 3.0% on a year-over-year basis, while earnings growth has been substantial at 143.0%. Additionally, the dividend yield stands at 260.0%, indicating that investors may be receiving significant returns in the form of dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Visit website →Key Statistics
- Market Cap
- $146.79B
- P/E Ratio
- 18.84
- 52-Week High
- $128.70
- 52-Week Low
- $88.57
- Avg Volume
- 6.90M
- Beta
- 0.35
- Dividend Yield
- 260.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NMS
- Country
- United States
- Employees
- 17,600